18F-PSMA-1007, Pluvicto 1 000 MBq/mL solution for injection/infusion clinical trials

Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.

This study is looking at a new treatment called Lutetium-177-PSMA for men with prostate cancer that hasn't spread widely and is sensitive to hormone therapy. It aims to see if this treatment can slow down the cancer's growth.